BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goyal H, Rahman MR, Perisetti A, Shah N, Chhabra R. Cannabis in liver disorders: a friend or a foe? Eur J Gastroenterol Hepatol 2018;30:1283-90. [PMID: 30169449 DOI: 10.1097/MEG.0000000000001256] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Greenberg R, Goldberg A, Anthony S, Buchman DZ, Delaney S, Gruben V, Holdsworth S, Le Foll B, Leung M, Lien D, Lynch MJ, Selzner N, Chandler JA, Fortin MC. Canadian Society of Transplantation White Paper: Ethical and Legal Considerations for Alcohol and Cannabis Use in Solid Organ Listing and Allocation. Transplantation 2021;105:1957-64. [PMID: 33587429 DOI: 10.1097/TP.0000000000003618] [Reference Citation Analysis]
2 Rivera P, Vargas A, Pastor A, Boronat A, López-Gambero AJ, Sánchez-Marín L, Medina-Vera D, Serrano A, Pavón FJ, de la Torre R, Agirregoitia E, Lucena MI, Rodríguez de Fonseca F, Decara J, Suárez J. Differential hepatoprotective role of the cannabinoid CB1 and CB2 receptors in paracetamol-induced liver injury. Br J Pharmacol 2020;177:3309-26. [PMID: 32167157 DOI: 10.1111/bph.15051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
3 Perisetti A, Gajendran M, Dasari CS, Bansal P, Aziz M, Inamdar S, Tharian B, Goyal H. Cannabis hyperemesis syndrome: an update on the pathophysiology and management. Ann Gastroenterol 2020;33:571-8. [PMID: 33162734 DOI: 10.20524/aog.2020.0528] [Reference Citation Analysis]
4 Berk K, Bzdega W, Konstantynowicz-Nowicka K, Charytoniuk T, Zywno H, Chabowski A. Phytocannabinoids-A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment. J Clin Med 2021;10:393. [PMID: 33498537 DOI: 10.3390/jcm10030393] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Andrews CN, Devlin SM, Le Foll B, Fischer B, Tse F, Storr M, Congly SE. Canadian Association of Gastroenterology Position Statement: Use of Cannabis in Gastroenterological and Hepatic Disorders. J Can Assoc Gastroenterol 2019;2:37-43. [PMID: 31294362 DOI: 10.1093/jcag/gwy064] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
6 Mathur K, Vuppalanchi V, Gelow K, Vuppalanchi R, Lammert C. Cannabidiol (CBD) Consumption and Perceived Impact on Extrahepatic Symptoms in Patients with Autoimmune Hepatitis. Dig Dis Sci 2020;65:322-8. [PMID: 31363952 DOI: 10.1007/s10620-019-05756-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
7 Perisetti A, Goyal H, Gajendran M, Boregowda U, Mann R, Sharma N. Prevalence, Mechanisms, and Implications of Gastrointestinal Symptoms in COVID-19. Front Med (Lausanne) 2020;7:588711. [PMID: 33195352 DOI: 10.3389/fmed.2020.588711] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
8 Perisetti A, Rimu AH, Khan SA, Bansal P, Goyal H. Role of cannabis in inflammatory bowel diseases. Ann Gastroenterol 2020;33:134-44. [PMID: 32127734 DOI: 10.20524/aog.2020.0452] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
9 Perisetti A, Gajendran M, Mann R, Elhanafi S, Goyal H. COVID-19 extrapulmonary illness - special gastrointestinal and hepatic considerations. Dis Mon. 2020;66:101064. [PMID: 32807535 DOI: 10.1016/j.disamonth.2020.101064] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]